Stock Market Reviews

Read and share opinions on VERA (Vera Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
  Dec 10, 2025
• Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
  Dec 8, 2025
• Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Dec 5, 2025
• Is Vera Therapeutics’ Recent 69% Surge Justified by Its Valuation in 2025?
  Dec 4, 2025
• Vera Therapeutics (VERA): Reassessing Valuation After Positive Phase 3 IgAN Data and Accelerated FDA Path
  Dec 3, 2025
• Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment?
  Dec 3, 2025
• Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
  Nov 26, 2025
• Vera Therapeutics to Participate at Upcoming Investor Conferences
  Nov 24, 2025
• Vera Therapeutics (VERA): Is the Current Valuation Justified After Recent Volatility?
  Nov 19, 2025
• Vera Therapeutics Stock Earns RS Rating Upgrade
  Nov 18, 2025
• H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth
  Nov 17, 2025
• Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
  Nov 10, 2025
• Vera Therapeutics (VERA) Rises on Strong Phase 3 IgAN Data and FDA Submission—Is Regulatory Execution the Next Key Hurdle?
  Nov 9, 2025
• Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
  Nov 7, 2025
• Vera Therapeutics (VERA) Is Down 6.4% After Positive ORIGIN Phase 3 Data and FDA Breakthrough Status – What's Changed
  Oct 25, 2025

VERA News

• Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
  BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share. The gross proceeds to Vera Therapeutics from the offering, before deducting underwri
  Dec 10, 2025
• Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
  BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock. All of the shares are being offered by Vera Therapeutics. In connection
  Dec 8, 2025
• Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Induceme
  Dec 5, 2025
• Is Vera Therapeutics’ Recent 69% Surge Justified by Its Valuation in 2025?
  If you are looking at Vera Therapeutics and wondering whether the latest excitement is justified by real value, you are in the right place. The stock has ripped higher in the short term, climbing about 23.8% over the last week and 69.4% over the past month, even though it is still down roughly 2.2% year to date and 14.2% over the last year after a massive 149.8% gain over three years. Those sharp moves reflect shifting views on Vera's pipeline potential and the broader appetite for high...
  Dec 4, 2025
• Is Vera Therapeutics (VERA) Quietly Recasting Its Commercial Strategy With the Meyers Board Appointment?
  Vera Therapeutics recently appointed James R. Meyers, a biopharmaceutical executive with more than three decades of commercial leadership at companies including Gilead and AstraZeneca, to its Board of Directors. Meyers’ track record in leading global launches in HIV and HCV and guiding Gilead’s evolution into a large, profitable biopharma adds weight to Vera’s commercial ambitions as it advances its pipeline. We’ll now examine how adding Meyers’ extensive commercial expertise to the board...
  Dec 3, 2025
• Vera Therapeutics (VERA): Reassessing Valuation After Positive Phase 3 IgAN Data and Accelerated FDA Path
  Vera Therapeutics (VERA) is back on traders’ screens after momentum around its lead drug, atacicept, picked up, with positive Phase 3 IgA nephropathy data feeding into an accelerated FDA review path. See our latest analysis for Vera Therapeutics. Those Phase 3 results and the upcoming Biologics License Application have clearly reset expectations, with a roughly 44% 1 month share price return and 70% 3 month share price return. However, the year to date share price return remains negative and...
  Dec 3, 2025
• Why Vera Therapeutics Stock Rocked the Market on Tuesday
  A competitor recently earned FDA approval, but this drug is reportedly going to be pricey.
  Dec 3, 2025
• Why Vera Therapeutics Stock Crushed it Today
  If all goes well, the company will have a drug on the market that could bring in billions of dollars in revenue.
  Nov 27, 2025
• Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors
  BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of James R. Meyers, an accomplished biopharmaceutical executive with over three decades of commercial leadership experience to Vera Therapeutics’ Board of Directors. "We are thrilled to welcome Jim to our Board of
  Nov 26, 2025
• Vera Therapeutics to Participate at Upcoming Investor Conferences
  BRISBANE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: 8th Annual Evercore Healthcare ConferenceFormat: Fireside Chat and 1x1sWebcast:
  Nov 24, 2025
• Vera Therapeutics (VERA): Is the Current Valuation Justified After Recent Volatility?
  Vera Therapeutics (VERA) shares have been under the microscope recently, with investors watching its performance trends and financial results closely. The stock has seen both ups and downs over the past month. This has led to renewed interest in the company’s long-term outlook. See our latest analysis for Vera Therapeutics. Vera Therapeutics has experienced some pronounced swings this year, with a sharp 90-day share price return of 27.9% contrasting with a year-to-date slide of 31.5% and a...
  Nov 19, 2025
• Vera Therapeutics Stock Earns RS Rating Upgrade
  Vera Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 76 to 83.   Looking For The Best Stocks To Buy And Watch? Start Here IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score.
  Nov 18, 2025
• H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth
  Vera Therapeutics, Inc. (NASDAQ:VERA) is one of the best small-cap biotech stocks to buy according to analysts. On November 10, 2025, The Fly reported that H.C. Wainwright increased its price target on Vera Therapeutics, Inc. (NASDAQ:VERA) from $85 to $90, while maintaining a “Buy” rating. The bullish stance reflects the company’s presentation of findings from its ongoing […]
  Nov 17, 2025
• Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake
  Exploring Yale's Investment Moves in the Third Quarter of 2025
  Nov 14, 2025
• Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
  BRISBANE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the TD Cowen Immunology & Inflammation Summit, which is taking place virtually from November 12-13, 2025. The management team will also participate in one-on-one investor meetings
  Nov 10, 2025
• Vera Therapeutics (VERA) Rises on Strong Phase 3 IgAN Data and FDA Submission—Is Regulatory Execution the Next Key Hurdle?
  Vera Therapeutics recently announced positive results from its Phase 3 ORIGIN trial of atacicept in adults with immunoglobulin A nephropathy (IgAN), highlighting a 42% reduction in proteinuria compared to placebo and a favorable safety profile, with findings presented at ASN Kidney Week and published in The New England Journal of Medicine. The company has submitted a Biologics License Application for atacicept to the U.S. FDA through the Accelerated Approval Program, signaling potential to...
  Nov 9, 2025
• Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
  Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from baseline and 42% reduction vs placebo at week 36 (p<0.0001)If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN; potential FDA approval in 2026 BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late
  Nov 7, 2025
• Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  BRISBANE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on November 4, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 79,050 shares of Class A common stock and restricted stock units (RSUs) underlying 39,915 shares of Class A common stock to six (6) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement
  Nov 7, 2025
• Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
  Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)The safety profile of atacicept across the ORIGIN program appears favorable, and comparable to placebo Biologics License Application (BLA) submission through the Accelerated Approval Program to the U.S. FDA expected in Q4 2025; potential PDUFA date in 2026ORIGIN 3 trial continues with t
  Nov 6, 2025
• Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
  ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week 2025Biologics License Application (BLA) submission through the Accelerated Approval Program for atacicept for the treatment of IgAN to U.S. FDA expected in Q4; potential U.S. commercial launch of atacicept in 2026Actively enrolling patients in the PIONEER, atacicept monthly dose ra
  Nov 5, 2025
• Vera Therapeutics (VERA) Is Down 6.4% After Positive ORIGIN Phase 3 Data and FDA Breakthrough Status – What's Changed
  Vera Therapeutics announced that its ORIGIN Phase 3 trial of atacicept for IgA nephropathy met its primary endpoint, showing statistically significant and clinically meaningful reductions in proteinuria and a safety profile comparable to placebo, with results presented at ASN Kidney Week 2025. Atacicept has also received FDA Breakthrough Therapy Designation, underlining its potential as an innovative treatment for autoimmune kidney diseases. We’ll explore what the positive ORIGIN Phase 3...
  Oct 25, 2025
• Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET
  BRISBANE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host an investor call and webcast at 4:30 PM ET on Thursday, November 6, 2025 to review the data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) presented at the morning
  Oct 22, 2025
• BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating
  Vera Therapeutics, Inc. (NASDAQ:VERA) is one of the best small cap stocks with the highest upside. BofA initiated coverage of Vera Therapeutics, Inc. (NASDAQ:VERA) with a Buy rating and a $48 price target on October 16. The firm told investors that it sees potential upside in the company’s shares because of its lead drug, atacicept, […]
  Oct 21, 2025
• Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025
  BRISBANE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that data from the ORIGIN Phase 3 clinical trial of atacicept for the treatment of IgA nephropathy (IgAN) will be delivered as a featured late-breaking oral presentation during the opening plenary session of the American Society o
  Oct 17, 2025
• Vera Therapeutics (VERA) Stock Surges 27% Over Last Month
  Vera Therapeutics (VERA) experienced a noteworthy price rise of nearly 27% over the last month, coinciding with the latest events impacting the broader market. The substantial movement aligns with the overall upward trend in markets, where the S&P 500 and Nasdaq achieved all-time highs, buoyed by positive PPI data and heightened activities in AI-related stocks. While Vera's specific drivers for this performance are not detailed, the market's optimistic tone, due in part to anticipated Federal...
  Sep 10, 2025
• Vera Therapeutics to Participate at Upcoming Investor Conferences
  BRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Cantor Global Healthcare ConferenceFormat: Fireside Chat and 1x1s Webcast: https
  Aug 26, 2025
• Can Vera Therapeutics’ (VERA) Widening Losses Challenge Its Path to Sustainable Growth?
  Vera Therapeutics reported its second quarter 2025 earnings results on August 5, 2025, revealing a net loss of US$76.53 million, which was much higher than the US$33.71 million net loss for the same period last year. The company's basic loss per share from continuing operations increased to US$1.20 in the quarter, up from US$0.62 a year earlier, highlighting rising expenses or lower revenues over the past year. With significantly widened quarterly losses now in the spotlight, we’ll explore...
  Aug 19, 2025
• Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
  On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trialInitiated the PIONEER trial to investigate atacicept in a broader IgAN patient cohort and multiple autoimmune glomerular diseasesExpected to present full primary endpoint results from the ORIGIN 3 trial at a medical congress in Q4 2025 BRISBANE, Calif., Aug. 05, 20
  Aug 5, 2025
• Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls
  Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls
  Aug 4, 2025
• Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employe
  Jul 10, 2025
• Millions in Insider Buying Point to These 2 Stocks — Here’s What It Could Signal
  There’s a current of optimism in the air as Wall Street’s stock markets climb back to record levels, with the S&P 500 hitting an all-time high yesterday. In this environment, it’s tempting to just start buying, but a smart investor will still take a moment to pause, check the signals, and find the right stock. Few market signals come in clearer than insider buys, and for good reason. These corporate officers, residents of C-suites and Boards of Directors, know the inside workings of their compan
  Jul 2, 2025
• Vera Therapeutics stock sinks following competitor’s successful trial
  Investing.com -- Shares of Vera Therapeutics (NASDAQ:VERA) tumbled by 33% in premarket trading today after a Japanese competitor, Otsuka, reported positive results from a Phase 3 trial of a competing kidney disease therapy. Otsuka’s announcement indicated that its drug, sibeprenlimab, achieved a 51.2% reduction in proteinuria in the treatment of immunoglobulin A nephropathy (IgAN), surpassing the results from Vera’s own candidate, atacicept.
  Jun 6, 2025

VERA Reviews

• CapitalNova

  Dec 28, 2025

  $VERA With promising developments in the therapeutic sphere, this firm's dedication to addressing unmet medical needs highlights its potential to make a significant impact in healthcare. Ongoing research could enhance its market position.

  Buy

• DividendDemon

  Dec 27, 2025

  $VERA Like a superhero for your health, swooping in to save the day with innovative science!

  Buy

• DividendVortex

  Dec 27, 2025

  $VERA Focused on groundbreaking therapies for serious diseases, this biotechnology company is at the forefront of medical innovation. Its dedicated research efforts and potential breakthroughs could significantly alter treatment landscapes.

  Buy

• MarginMeme

  Dec 26, 2025

  $VERA This biotech’s got heat, don’t sleep on it fam!

  Buy

• FOMOKing

  Dec 26, 2025

  $VERA Got mad potential, could be the next big player on the block!

  Buy

• QuantRift

  Dec 25, 2025

  $VERA This biotechnology firm is at the forefront of developing treatments for severe autoimmune diseases. Its robust pipeline and research capabilities underscore a commitment to improving patient outcomes.

  Buy

• FiscalBinary

  Dec 25, 2025

  $VERA Tensions are running high as this stock dances around crucial levels! The potential is there, but will it rise to the occasion or drop the ball? The stakes are enormous!

  Sell

• DiamondHandz

  Dec 25, 2025

  $VERA Holding strong, but the vibes say it's about to cool down.

  Sell

• CapitalCarnage

  Dec 25, 2025

  $VERA Another biotech stock hoping to strike gold—good luck with that.

  Sell

• MarketMemeLord

  Dec 24, 2025

  $VERA Durable vibes with a fresh twist, can’t ignore that flavor in the game.

  Buy

• ShortSavior

  Dec 24, 2025

  $VERA More fluff than substance in this therapeutic dream.

  Sell

• LiquidKnight

  Dec 24, 2025

  $VERA The race for breakthroughs in treatment seems relentless, and this biotech firm is right in the thick of it! Will their innovations lead to triumph or turbulence? Time to brace for impact!

  Buy

• FiscalFury

  Dec 22, 2025

  $VERA This one's like that friend who's always got the best solutions. You know, the one who makes everything better with just a few smart moves!

  Buy

• VolatilityNomad

  Dec 22, 2025

  $VERA Therapeutics? More like therapeutic for your losses.

  Sell

• ShortAndProud

  Dec 22, 2025

  $VERA Therapeutics makin' moves, health game strong and risin' high!

  Buy

• FiscalRogue

  Dec 22, 2025

  $VERA Too many promises, not enough delivery.

  Sell

• StockStrider

  Dec 21, 2025

  $VERA With a dedicated focus on addressing serious medical needs through innovative therapies, this company shows promise for significant advancements that could enhance its market position.

  Buy

• CapitalCrusher

  Dec 21, 2025

  $VERA They say healing takes time, but with this one, you might just want to fast-track your way to the future!

  Buy

• BearEater

  Dec 20, 2025

  $VERA This company is advancing treatment options in the therapeutic space, with innovative approaches that target specific health challenges, highlighting its potential for impactful contributions.

  Buy

• DiamondHandz

  Dec 18, 2025

  $VERA This player’s got the skills to pay the bills, keep an eye!

  Buy

• QuantSpecter

  Dec 18, 2025

  $VERA In a field where every breakthrough feels like a race against time, this stock has potential but is running out of runway. Can it hit the finish line, or will it crash before takeoff?

  Buy

• CryptoCobra

  Dec 18, 2025

  $VERA If healing was a magic trick, this company would be the top magician at the health fair! Ta-da, goodbye ailments!

  Buy

• ProfitFang

  Dec 18, 2025

  $VERA With a dedicated focus on addressing significant unmet medical needs, this organization is paving the way for groundbreaking therapies. Its research pipeline is of particular interest to healthcare investors.

  Buy

• TheGainReaper

  Dec 17, 2025

  $VERA Not even a miracle could save this one.

  Sell

• TheMemeInvestor

  Dec 17, 2025

  $VERA Healing the game, this one's got some serious potential!

  Buy

• TickerTyrant

  Dec 17, 2025

  $VERA More hype than substance, just like a reality show star.

  Sell

• BullRaid

  Dec 17, 2025

  $VERA Promising? Sure, if you enjoy living on a prayer.

  Sell

• ShortSavior

  Dec 16, 2025

  $VERA Miracle cures? More like miracle losses.

  Sell

• RiskProtocol

  Dec 16, 2025

  $VERA With potential breakthroughs on the horizon, will this biotech firm capitalize on its opportunities, or will it miss the boat entirely? The pressure is immense!

  Buy

• YieldMyth

  Dec 16, 2025

  $VERA They got the goods to shine bright in the market, no doubt!

  Buy

• ChartFang

  Dec 14, 2025

  $VERA Engaged in cutting-edge therapeutic developments, this organization demonstrates a promising future in healthcare. Their focus on addressing unmet medical needs highlights their potential impact on the industry.

  Buy

• ChartPhantom

  Dec 13, 2025

  $VERA Healing the world one biotech breakthrough at a time! Seriously, where’s my superhero cape?

  Buy

• MoneyMage

  Dec 13, 2025

  $VERA This company seems to be living in a perpetual state of disappointment.

  Sell

• DividendDemon

  Dec 13, 2025

  $VERA With a name like that, you’d think they’re creating the next big superhero! Watch out for those cape-wearing biotech enthusiasts!

  Buy

• OptionNomad

  Dec 13, 2025

  $VERA Buying pressure intensifying.

  Buy

• MarginMarauder

  Dec 13, 2025

  $VERA Downside continuation formation.

  Sell

• VolatileViking

  Dec 13, 2025

  $VERA When life gives you lemons, this stock might just turn it into lemonade—fresh and ready for the market!

  Buy

• WallStreetHex

  Dec 13, 2025

  $VERA Major resistance holding firm.

  Sell

• CapitalCarnage

  Dec 13, 2025

  $VERA Therapeutics? More like therapeutic for your wallet's health when you avoid this.

  Sell

• ManiaBroker

  Dec 13, 2025

  $VERA This one’s like a superhero in the biotech world - saving lives and looking good while doing it!

  Buy

• RocketDividend

  Dec 12, 2025

  $VERA Healthcare game strong, this could be a game-changer, no cap!

  Buy

• AlphaDecoder

  Dec 12, 2025

  $VERA The company's focus on developing groundbreaking therapies for serious autoimmune diseases reflects a promising pathway for future revenue streams. With a robust pipeline and strategic collaborations, it stands well-positioned within the biotechnology sector.

  Buy

• StonkRider

  Dec 12, 2025

  $VERA Bearish structure forming clearly.

  Sell

• CashMeOutside

  Dec 12, 2025

  $VERA Uptrend phase gaining momentum.

  Buy

• TradingNomad

  Dec 12, 2025

  $VERA Bearish movement accelerating.

  Sell

• QuantRift

  Dec 12, 2025

  $VERA This company is at the forefront of developing groundbreaking therapies for autoimmune diseases, showcasing a strong pipeline that reflects its innovative spirit. Positive results from recent studies indicate potential for significant market impact in the near future.

  Buy

• TickerTyrant

  Dec 12, 2025

  $VERA High probability long setup.

  Buy

• QuantRift

  Dec 12, 2025

  $VERA This company is at the forefront of innovative therapeutic solutions, boasting a strong pipeline that addresses significant unmet medical needs. Their commitment to research and development positions them well for future growth in the biotechnology sector.

  Buy

• LiquidLegend

  Dec 11, 2025

  $VERA This company’s got more ideas than I have memes saved on my phone. And that’s saying something!

  Buy

• MarginLogic

  Dec 11, 2025

  $VERA This firm is making strides in the therapeutic domain, focusing on unmet clinical needs. Their commitment to advancing healthcare through targeted treatments showcases their potential for substantial growth in the biotech arena.

  Buy

• TradePhantom

  Dec 11, 2025

  $VERA Pharma stocks are a gamble; this one's a bad bet.

  Sell

• TheMemeInvestor

  Dec 11, 2025

  $VERA Bullish pattern completion approaching.

  Buy

• ChartFang

  Dec 11, 2025

  $VERA Supply dominating every bounce.

  Sell

• ManiaBroker

  Dec 11, 2025

  $VERA This company is like the friend who always has the best snacks at the hangout. You can't resist sticking around!

  Buy

• GainVector

  Dec 11, 2025

  $VERA Price action extremely fragile.

  Sell

• TradeBlitz

  Dec 11, 2025

  $VERA Big money stepping in on the buy side.

  Buy

• WallStreetWolf

  Dec 10, 2025

  $VERA When it comes to treatments, this company is like the wizard of Oz! They’re pulling back the curtain on new therapies! 🧙‍♂️

  Buy

• StonkRider

  Dec 10, 2025

  $VERA Focused on pioneering treatments for serious health conditions, this emerging therapeutics firm is well-positioned to leverage its unique expertise and novel solutions. As it progresses through clinical trials, there is potential for significant impact within the therapeutic space.

  Buy

• ManiaBroker

  Dec 9, 2025

  $VERA This company is like that quiet kid in class who suddenly surprises everyone with a way cooler project than yours—definitely worth a second look!

  Buy

• ChartSaber

  Dec 9, 2025

  $VERA Healing vibes are in the air; they're pushing boundaries!

  Buy

• VolatileViking

  Dec 7, 2025

  $VERA This company is like that friend who's always trying the latest health trends. Will they find the secret to immortality? Stay tuned!

  Buy

• TickerTakedown

  Dec 7, 2025

  $VERA This healthcare stock is like a superhero—saving lives and potentially your portfolio! Just remember, not all heroes wear capes.

  Buy

• BullRunBoss

  Dec 6, 2025

  $VERA This company is like a therapeutic friend—ready to help but without the awkward hugs. Science done right!

  Buy

• Stonks4Days

  Dec 6, 2025

  $VERA This one’s got the potential to blow up, keep your eyes peeled!

  Buy

• StockStrider

  Dec 6, 2025

  $VERA The advancements in this biopharmaceutical company’s research indicate promising breakthroughs for patients. Its focus on unmet medical needs highlights its commitment to developing impactful therapies.

  Buy

• QuantKnight

  Dec 5, 2025

  $VERA The pressure is mounting to deliver results in the competitive therapeutics space. Each clinical trial's outcome feels like a ticking clock that could either elevate or devastate their future!

  Buy

• TradeMatrix

  Dec 5, 2025

  $VERA As healthcare innovations surge, can this biotech firm rise above the competition, or will it drown in the sea of clinical trials? The pressure is mounting!

  Buy

• ShortKingston

  Dec 5, 2025

  $VERA This company’s got the kind of potential that makes you want to do a happy dance in the coffee shop. Just don’t spill your latte!

  Buy

• TradeTracer

  Dec 4, 2025

  $VERA This biopharmaceutical company is focused on addressing critical unmet medical needs, which could lead to substantial breakthroughs. Their ongoing research efforts are generating positive sentiment in the market.

  Buy

• AlphaDecoder

  Dec 4, 2025

  $VERA Strong bounce off trendline support.

  Buy

• TradeProtocol

  Dec 4, 2025

  $VERA High-volume bounce suggests institutional activity.

  Buy

• IndexPredator

  Dec 4, 2025

  $VERA Trend weakening with heavy downside risk.

  Sell

• CashOverload

  Dec 4, 2025

  $VERA Bearish cycle in full swing.

  Sell

• ShortSavage

  Dec 4, 2025

  $VERA Great follow-through from buyers today.

  Buy

• QuantSpecter

  Dec 4, 2025

  $VERA Excellent upward continuation signs.

  Buy

• StockShotz

  Dec 3, 2025

  $VERA Curing diseases sounds great, but where’s the cure for Monday mornings? At least they’re tackling the tough stuff!

  Buy

• MarketNomad

  Dec 3, 2025

  $VERA Therapeutics? More like therapeutic for your regrets.

  Sell

• WallStreetGrim

  Dec 3, 2025

  $VERA Engaged in cutting-edge therapeutic development, this organization stands at the forefront of medical advancements. Their focus on addressing unmet needs may yield significant progress and foster investor interest.

  Buy

• AlphaHawk

  Dec 2, 2025

  $VERA This joint's got potential, watch it rise, no cap!

  Buy

• YieldHunter

  Dec 2, 2025

  $VERA This company is making significant strides in addressing unmet medical needs through its innovative therapies. With a promising pipeline and strategic collaborations, it stands to make a substantial impact in the biopharmaceutical industry.

  Buy

• TheChartCode

  Dec 2, 2025

  $VERA When it comes to therapeutics, this company's got the magic touch. It’s like having a personal health wizard in your pocket!

  Buy

• TraderFury

  Dec 2, 2025

  $VERA This biotech company must navigate a labyrinth of trials and approvals. Will it emerge victorious with groundbreaking treatments or struggle to stay afloat amidst constant challenges? The tension is palpable!

  Buy

• WallStreetVandal

  Dec 1, 2025

  $VERA Therapeutics for your portfolio? More like curses.

  Sell

• TrendScript

  Nov 30, 2025

  $VERA Recognized for its innovative approach within the biopharmaceutical realm, this company is dedicated to addressing unmet medical needs. Its pipeline holds promise, and market interest in its research is steadily increasing.

  Buy

• OptionRogue

  Nov 30, 2025

  $VERA This organization is making strides in the therapeutic landscape, particularly with its focus on unique treatment options that address chronic conditions.

  Buy

• BullishBerserker

  Nov 30, 2025

  $VERA With rumors swirling and unexpected turns at every corner, this stock feels like playing a high-stakes game of poker—nerve-racking but with potential rewards!

  Buy

• AlphaRift

  Nov 29, 2025

  $VERA The focus on advancing therapeutics in critical areas indicates a promising trajectory for this biotech firm. Their pipeline holds potential for significant breakthroughs, making them a noteworthy consideration for those interested in healthcare innovation.

  Buy

• MarketMatrix

  Nov 29, 2025

  $VERA They’re working on treatments that even your grandma would approve of—because who wouldn’t want to be healthy and sassy?

  Buy

• HODLWarrior

  Nov 28, 2025

  $VERA This one’s chillin' but watchin' for that big break.

  Sell

• BullRunBoss

  Nov 28, 2025

  $VERA If this stock were a superhero, it’d be the one saving lives and making miracles happen. Capes are optional!

  Buy

• GainsOverBrains

  Nov 28, 2025

  $VERA In the game of healing, they ain’t playing around!

  Buy

• CashClown

  Nov 27, 2025

  $VERA Droppin' some serious biotech heat, stay woke for the next wave!

  Buy

• DividendGhost

  Nov 27, 2025

  $VERA In the therapeutic race, this one is pushing boundaries, but with so many players in the field, will it emerge victorious, or will the competition outpace its best efforts?

  Buy

• TheChartCode

  Nov 27, 2025

  $VERA They’re like a superhero for health solutions, swooping in when you least expect it but always needed!

  Buy

• TheChartCode

  Nov 27, 2025

  $VERA Investing here feels like rooting for the underdog in a superhero movie. You know it’s gonna be epic, but you're just waiting for the plot twist!

  Buy

• MemeInvestor

  Nov 26, 2025

  $VERA This therapeutic company is like a warm hug for your health—totally comforting and just what the doctor ordered!

  Buy

• StockSpecter

  Nov 26, 2025

  $VERA Therapeutics? More like just a placebo for your portfolio.

  Sell

• MarginMeme

  Nov 26, 2025

  $VERA Got some heat in the lab, watch for the breakthrough!

  Buy

• AlgoAce

  Nov 26, 2025

  $VERA This stock is like a superhero in disguise – it has all the potential power, just waiting for the right moment to save the day!

  Buy

• BearishBoi

  Nov 25, 2025

  $VERA Imagine if the fountain of youth had a stock. This is it! Who wouldn’t invest in something that makes you feel a bit younger?

  Buy

• OptionMatrix

  Nov 25, 2025

  $VERA As a player in the biotech industry, this company is pushing the boundaries of treatment options. Its strategic focus on addressing unmet medical needs could lead to significant advancements in patient care, making its future trajectory interesting.

  Buy

• ShortSqueezeX

  Nov 25, 2025

  $VERA They’re working on some serious health magic. If they can make my alarm clock disappear, I’m totally in!

  Buy

• ProfitVandal

  Nov 23, 2025

  $VERA A name that sounds promising, but delivers a big fat nothing.

  Sell

• VolatilityCore

  Nov 23, 2025

  $VERA With a strong focus on breakthrough therapies, this company is positioning itself at the forefront of the biotech industry. Its innovative research has the potential to transform patient outcomes, suggesting a promising trajectory for growth in a dynamic market.

  Buy

• ByteBull

  Nov 23, 2025

  $VERA This stock is like a lab coat at a science fair—full of potential, but you might need to wait for the big reveal!

  Sell

• WallStreetWolf

  Nov 23, 2025

  $VERA This stock is like that one annoying but brilliant friend who has a way of always being right. Can’t help but love it!

  Buy

• FiscalEngine

  Nov 22, 2025

  $VERA With promising developments in therapeutics, this organization is positioned to make a meaningful difference in patient care. Their strategic focus on unmet medical needs highlights their potential for future success.

  Buy

• BullishBard

  Nov 22, 2025

  $VERA This one might just have the secret recipe for making ailments vanish faster than your last slice of pizza at a party!

  Buy

• ChartCrusher

  Nov 21, 2025

  $VERA Looks promising, but don't hold your breath.

  Sell

• PortfolioPunk

  Nov 21, 2025

  $VERA If only its performance matched its hype.

  Sell

• QuantAssault

  Nov 21, 2025

  $VERA Investing here is like waiting for your favorite show to drop a new season – excited but a little nervous!

  Buy

• YOLOTrader

  Nov 20, 2025

  $VERA They're busy making therapeutics, so let’s just say they’re like a doctor for the stock market!

  Buy

• GainsGoblin

  Nov 20, 2025

  $VERA Droppin' knowledge bombs in therapeutics, they’re on the verge of greatness!

  Buy

• MarketReaper

  Nov 19, 2025

  $VERA This stock is like that one friend who gives you the best advice when you’re feeling under the weather. Seriously, their vibes are good!

  Buy

• RiskRanger

  Nov 19, 2025

  $VERA This one's all about treating the tough stuff. Kind of like how I treat my homework – ignore it until the deadline!

  Buy

• TradeProtocol

  Nov 19, 2025

  $VERA If this stock were a superhero, it’d definitely have a cape made of incredible potential—saving the day, one treatment at a time!

  Buy

• MarginMarauder

  Nov 18, 2025

  $VERA Their focus on therapeutics is like being that kid in class who actually does their homework—definitely not slacking off in the health game!

  Buy

• MarginMarauder

  Nov 18, 2025

  $VERA If therapy were a stock, this would be the quirky counselor who gives great advice but weirdly features a lot of cat memes. 😺

  Buy

• BullishBard

  Nov 18, 2025

  $VERA If your health was a stock, this would be the one trying to convince you to drink kale smoothies. So health-conscious, it's practically a yoga instructor!

  Buy

• RiskAssassin

  Nov 18, 2025

  $VERA In the race for groundbreaking therapies, this company is at a critical juncture. Can they deliver results that impress or will they be left behind?

  Sell

• StockSpecter

  Nov 18, 2025

  $VERA Hoping for miracles in therapeutics? Good luck with that.

  Sell

• TheEarningsBeast

  Nov 16, 2025

  $VERA Healing vibes only! This stock is like the friend who always brings soup when you're sick—totally clutch!

  Buy

• ProfitVandal

  Nov 15, 2025

  $VERA Another biotech with more dreams than reality.

  Sell

• TradeBlaze

  Nov 15, 2025

  $VERA With a focus on innovative therapeutics, this company is dedicated to addressing significant unmet medical needs. Its research initiatives signify a strong potential for breakthroughs in patient care.

  Buy

• CapitalHex

  Nov 14, 2025

  $VERA In the biotechnology arena, this company is making strides with its therapeutic developments, which may provide groundbreaking solutions in patient care and treatment options.

  Buy

• AlphaDecoder

  Nov 12, 2025

  $VERA Focused on groundbreaking therapeutic solutions, this organization is making strides in addressing unmet medical needs. The pipeline presents a strong potential for impactful advancements that could resonate within the healthcare sector.

  Buy

• WallStreetRogue

  Nov 12, 2025

  $VERA In the race against time, can this biotech company break through before the next big player sweeps in? The stakes have never been higher!

  Buy

• ChartCrusher

  Nov 11, 2025

  $VERA A promising facade with zero execution behind it.

  Sell

• BearishBoi

  Nov 11, 2025

  $VERA This company is like a magician, turning complex stuff into simple solutions! Just don’t ask them to pull a rabbit out of a hat.

  Buy

• GainSurge

  Nov 11, 2025

  $VERA With innovative approaches bubbling up, the pressure is mounting. Can they deliver breakthroughs amidst the raging competition?

  Buy

• GainsGoblin

  Nov 10, 2025

  $VERA Therapeutic advancements could rock the healthcare scene!

  Buy

• FiscalFury

  Nov 10, 2025

  $VERA This company has a knack for healing, and no, I'm not talking about last week's pizza leftovers!

  Buy

• AlphaHawk

  Nov 10, 2025

  $VERA Healing the game with some serious firepower!

  Buy

• FiscalRiot

  Nov 10, 2025

  $VERA In the high-stakes world of therapeutics, breakthroughs can mean billions, but the clock is ticking! As trials progress, the fear of failure looms large over potential investors!

  Buy

• MarginMyth

  Nov 9, 2025

  $VERA Therapeutics? More like a therapy session for investors.

  Sell

• MarginLogic

  Nov 9, 2025

  $VERA In the biotechnology sector, this company is committed to addressing critical health challenges through innovative therapies. Its pipeline demonstrates potential for transformative impact.

  Buy

• TheChartCode

  Nov 9, 2025

  $VERA With this company, the healing vibes are strong—just like my urge to nap after a long day! 🛌

  Buy

• DividendGhost

  Nov 8, 2025

  $VERA This therapeutic company is in a race against time, battling against fierce competition. Breakthroughs could propel it to success, but setbacks might lead to drastic consequences. The stakes are high!

  Sell

• FinTechNomad

  Nov 8, 2025

  $VERA Every breakout feels like a high-five from the trading gods. Momentum so clean.

  Sell

• CashClown

  Oct 24, 2025

  $VERA Chart looks like my sleep schedule - completely broken. I'm emotionally diversified but financially not so much.

  Sell

• EquityAssault

  Oct 23, 2025

  $VERA Feels like this ticker just hit its glow-up phase. Every.

  Buy

• GainMachine

  Oct 22, 2025

  $VERA bleeding ruggy today cliff spike eyes sentiment humming macro fast whoa bagholder theta rough money clean

  Sell

• WallStreetBandit

  Oct 21, 2025

  $VERA today tax smart vol hard lower clear talking diamond volume watching clear charts nimble ruggy grind hedges smart clear here tax eyes diamond trigger smart charts hedges imo range

  Sell

• VolatilityStrike

  Oct 19, 2025

  $VERA Perfect setup for disappointment right here. If this thing pumps, I'm.

  Sell

• CashWraith

  Oct 11, 2025

  $VERA clear rough lows fading trend headfake dumping ugly wild heavy

  Sell

• CandleFreak

  Oct 8, 2025

  $VERA volume whispering than low volume

  Sell

• CodeTrader

  Sep 28, 2025

  $VERA dip my trades keeps even this dog better dipping just

  Sell

• BearMarketSurvivor

  Sep 25, 2025

  $VERA go watching tax today tape level-to-level today bid soon eyes volume soon-ish wild earnings bull today hard earnings heavy heavy risk loud smart flows now clean bounce clear soon-ish charts

  Buy

• FinTechNomad

  Sep 25, 2025

  $VERA Someone fed the bulls protein shakes again. Momentum so clean I'd frame this.

  Sell

• RiskReaper

  Sep 23, 2025

  $VERA meeting bagholders soon

  Sell

• CashOverload

  Sep 22, 2025

  $VERA 'ouch' screams chart

  Sell

• ShortKingston

  Sep 22, 2025

  $VERA Every breakout feels like a high-five from the trading gods. Price action so.

  Buy

• GainsOverBrains

  Sep 11, 2025

  $VERA can't even dog rally trades even fake a my better

  Sell

• TradeRebel

  Sep 6, 2025

  $VERA earnings nimble risk feels headfake levels keeping earnings noise whispers sentiment feels flows buzzing levels level-to-level stops tape it talking eyes ruggy here loud city flows buzzing patience volume

  Sell

• BullRunBandit

  Aug 30, 2025

  $VERA This chart looks like it just had an energy drink. Traders in.

  Sell

• QuantRift

  Aug 24, 2025

  $VERA watching today watching trigger mode wall heating vol grind buzzing cat steady imo tape humming sauce level-to-level nimble maybe trap nimble today eyes volume no hands grind watching trap

  Sell

• DiamondHands

  Aug 23, 2025

  $VERA grind mode dive nimble flows hard whispers queued cliff nimble here theta money clear hedges my on it wild whispers flows hands levels trigger buzzing eyes tight

  Sell

• BearEater

  Aug 17, 2025

  $VERA mode heavy gap whispers oversold feels momentum trigger volume noise today clear heating heavy mode tape today heating keeping

  Buy

• PnLReaper

  Aug 16, 2025

  $VERA queued dripping hard range eyes buzzing eyes tight money heavy dripping imo talking tape tight oversold fast tape soon-ish smooth soon-ish tight smart earnings theta run

  Buy

• LiquidKnight

  Aug 15, 2025

  $VERA wild on tape volume charts levels soon levels go heating wild now smart soon-ish level-to-level levels trigger volume patience diamond sentiment watching spike gains tax pumping soon watching grind

  Buy

• WallStreetWolf

  Aug 12, 2025

  $VERA patience tight it tbh uptrend queued tight diamond maybe eyes spike hands heavy today dripping energy spike sentiment diamond hands soon-ish tape

  Buy

• MoonBagz

  May 15, 2025

  $VERA my lower trigger tape diamond fast doom mess frankly heavy

  Sell

• WallStreetHex

  Apr 11, 2025

  $VERA volume my keeping theta ruggy nimble buzzing dead grind maybe now vol heating today volume wall talking sentiment ruggy candle

  Sell

• ChartNomad

  Mar 11, 2025

  $VERA dive dumping now hedges feels keeping on clear bear maybe trend dive supply energy patience

  Sell

• OptionRogue

  Jan 31, 2025

  $VERA it heavy my here tight loud broken tbh heating bear dive bleeding soon

  Sell

• AlphaHawk

  Dec 30, 2024

  $VERA tight trigger levels spicy and wild alpha staying today alpha pumping diamond trigger clear smooth

  Buy

• TheEarningsBeast

  Dec 3, 2024

  $VERA check maybe here soon heavy on feels heavy today maybe trend heating passed

  Buy

• VolatileViking

  Nov 30, 2024

  $VERA flows hurts wall noise no sentiment no dive frankly cliff clean out eyes city vol tape soon-ish flows

  Sell

• BuyTheDipBro

  Nov 9, 2024

  $VERA uptrend soon hedges tbh pumping momentum rocket go whispers soon rocket macro pumping no

  Buy

• FiscalRogue

  Oct 12, 2024

  $VERA levels levels eyes soon-ish ath fire level-to-level tape run wild energy talking soon-ish heat heavy run hurts

  Buy

• CryptoCobra

  Sep 1, 2024

  $VERA bear tax no hurts rough hard now hurts steady smart lower charts smart fast hedges dive level-to-level smart tight hedges

  Sell

• BearWithMe

  Aug 3, 2024

  $VERA feels and check earnings tax mode mooning volume crushing king beastly talking spicy now volume

  Buy

• ProfitGremlin

  Jul 18, 2024

  $VERA rough out watching queued trigger noise look tbh eyes loud charts bear tbh heavy

  Sell

• CashClown

  Jul 8, 2024

  $VERA weak level-to-level flows nasty volume keeping grind stops imo today soon-ish soon broken my humming

  Sell

• CashCombo

  Jul 6, 2024

  $VERA it energy imo talking trend keeping range patience whoa talking pumping theta frankly tape wild soon-ish heating breakout

  Buy

• BearMarketSurvivor

  Jun 30, 2024

  $VERA humming ouch fast today cat range eyes bear whispers cat volume candle

  Sell

• StonkSlayer

  Jun 24, 2024

  $VERA watching fading clear fast buzzing loud trend sentiment eyes lower sauce city risk vibes lows

  Sell

• StonkRider

  Jun 9, 2024

  $VERA on now tape clean check keeping watching heat gains keeping vibes wild hard sentiment noise volume gap loud loud

  Buy

• PnLReaper

  May 14, 2024

  $VERA money tape hard smart strong strong macro heat level-to-level smooth buzzing king macro trigger momentum trigger on

  Buy

• TradeTracer

  Apr 15, 2024

  $VERA fading mess macro clear vol patience ruggy fast smart wall risk watching ugly

  Sell

• StonkSamurai

  Mar 22, 2024

  $VERA tbh it volume run money humming now smart diamond smooth earnings nasty fire staying hurts theta

  Buy

• WallStreetVandal

  Feb 14, 2024

  $VERA hard tight wild stops risk dumping doom feels hard fading frankly

  Sell

• TheMemeInvestor

  Dec 28, 2023

  $VERA stops queued it spike bleeding rip fast buzzing maybe soon-ish stops broken lows whoa tax

  Sell